Searching News Database: chemotherapy
Your search returned too many results! The most recent 500 items are shown below:
HSMN NewsFeed - 3 Apr 2024
Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement
Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement
HSMN NewsFeed - 28 Feb 2024
Bexion Pharmaceuticals, Inc. Appoints Dr. Tariq Arshad as Chief Medical Officer
Bexion Pharmaceuticals, Inc. Appoints Dr. Tariq Arshad as Chief Medical Officer
HSMN NewsFeed - 18 Dec 2023
NeuExcell's AAV Gene Therapy for Malignant Glioma Granted Orphan Drug Designation by FDA
NeuExcell's AAV Gene Therapy for Malignant Glioma Granted Orphan Drug Designation by FDA
HSMN NewsFeed - 8 Dec 2022
Dantari Debuts with $47 Million Series A to Advance Best-in-Class Targeted Medicines for Solid Tumors
Dantari Debuts with $47 Million Series A to Advance Best-in-Class Targeted Medicines for Solid Tumors
HSMN NewsFeed - 25 Oct 2022
Actinium Bolsters its Senior Leadership Team Ahead of Upcoming Clinical Data for Iomab-B
Actinium Bolsters its Senior Leadership Team Ahead of Upcoming Clinical Data for Iomab-B
HSMN NewsFeed - 22 Sep 2022
FDA Grants QT Imaging(TM) Clearance to Calculate Fibroglandular Volume of the Breast
FDA Grants QT Imaging(TM) Clearance to Calculate Fibroglandular Volume of the Breast
HSMN NewsFeed - 27 May 2022
Accord Healthcare Adds Pemetrexed Lyo. Injection to Generic Drug Portfolio
Accord Healthcare Adds Pemetrexed Lyo. Injection to Generic Drug Portfolio
HSMN NewsFeed - 4 Oct 2021
C-RAD and Accuray Sign Agreement to Enhance Radixact(R) System Breast Cancer Treatment Capabilities
C-RAD and Accuray Sign Agreement to Enhance Radixact(R) System Breast Cancer Treatment Capabilities
HSMN NewsFeed - 27 Sep 2021
Japan's MHLW Approves PADCEV(R) (enfortumab vedotin) for Advanced Urothelial Cancer
Japan's MHLW Approves PADCEV(R) (enfortumab vedotin) for Advanced Urothelial Cancer
HSMN NewsFeed - 26 Mar 2021
European Medicines Agency Accepts Marketing Authorization Application for Enfortumab Vedotin
European Medicines Agency Accepts Marketing Authorization Application for Enfortumab Vedotin
HSMN NewsFeed - 18 Mar 2021
Boston Scientific Receives FDA Approval for TheraSphere(TM) Y-90 Glass Microspheres
Boston Scientific Receives FDA Approval for TheraSphere(TM) Y-90 Glass Microspheres
HSMN NewsFeed - 24 Feb 2021
Clarus Therapeutics Appoints Richard 'Ric' Peterson as Chief Financial Officer
Clarus Therapeutics Appoints Richard 'Ric' Peterson as Chief Financial Officer
HSMN NewsFeed - 1 Dec 2020
Actinium Appoints Mary Mei Chen, M.D., Ph.D. as Vice President of Clinical Development
Actinium Appoints Mary Mei Chen, M.D., Ph.D. as Vice President of Clinical Development
HSMN NewsFeed - 18 Sep 2020
BrainCool Announces Statistically Significant Late-Breaking Clinical Data at ESMO Virtual Congress 2020
BrainCool Announces Statistically Significant Late-Breaking Clinical Data at ESMO Virtual Congress 2020
HSMN NewsFeed - 18 Aug 2020
Innovent and Lilly Announce Expansion of TYVYT(R) (Sintilimab Injection) Licensing Agreement
Innovent and Lilly Announce Expansion of TYVYT(R) (Sintilimab Injection) Licensing Agreement
HSMN NewsFeed - 27 Jul 2020
AxoProtego Therapeutics Announces Novel Investigational Agent for Chemotherapy-Induced Peripheral Neuropathy
AxoProtego Therapeutics Announces Novel Investigational Agent for Chemotherapy-Induced Peripheral Neuropathy
HSMN NewsFeed - 23 Jul 2020
Quadriga BioSciences Initiates Clinical Trial of Innovative, Targeted Treatment for Brain Cancers
Quadriga BioSciences Initiates Clinical Trial of Innovative, Targeted Treatment for Brain Cancers
HSMN NewsFeed - 23 Jun 2020
Polynoma Receives FDA Fast Track Designation for its Melanoma Cancer Vaccine Seviprotimut-L
Polynoma Receives FDA Fast Track Designation for its Melanoma Cancer Vaccine Seviprotimut-L
HSMN NewsFeed - 11 Jun 2020
CNS Announces the FDA has Granted Orphan Drug Designation for Brain Cancer Drug Berubicin
CNS Announces the FDA has Granted Orphan Drug Designation for Brain Cancer Drug Berubicin
HSMN NewsFeed - 26 May 2020
Elevar Therapeutics Appoints Mark Gelder, M.D. as Global Head of Medical Affairs
Elevar Therapeutics Appoints Mark Gelder, M.D. as Global Head of Medical Affairs
HSMN NewsFeed - 25 Mar 2020
Elevar Therapeutics Acquires Global Rights to European Approved Apealea(R) from Oasmia Pharmaceutical
Elevar Therapeutics Acquires Global Rights to European Approved Apealea(R) from Oasmia Pharmaceutical
HSMN NewsFeed - 24 Mar 2020
Apexigen Completes $123 Million Series C Financing To Advance Clinical Pipeline
Apexigen Completes $123 Million Series C Financing To Advance Clinical Pipeline
HSMN NewsFeed - 13 Mar 2020
EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study
EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study
HSMN NewsFeed - 12 Mar 2020
Agenus Receives Fast Track Designation for Balstilimab & Zalifrelimab in Advanced Cervical Cancer
Agenus Receives Fast Track Designation for Balstilimab & Zalifrelimab in Advanced Cervical Cancer
HSMN NewsFeed - 13 Feb 2020
Decipher GRID Signature Predicts Benefit from Chemotherapy in Men Diagnosed with Metastatic Prostate Cancer
Decipher GRID Signature Predicts Benefit from Chemotherapy in Men Diagnosed with Metastatic Prostate Cancer
HSMN NewsFeed - 29 Jan 2020
Lilly Receives FDA Priority Review for the Selpercatinib New Drug Application
Lilly Receives FDA Priority Review for the Selpercatinib New Drug Application
HSMN NewsFeed - 26 Nov 2019
CNS Pharmaceuticals Entered $2.0 Million Sublicense Agreement with WPD Pharmaceuticals
CNS Pharmaceuticals Entered $2.0 Million Sublicense Agreement with WPD Pharmaceuticals
HSMN NewsFeed - 19 Nov 2019
CNS Pharmaceuticals Acquired Worldwide Rights for Brain Cancer Drug from Houston Pharmaceuticals
CNS Pharmaceuticals Acquired Worldwide Rights for Brain Cancer Drug from Houston Pharmaceuticals
HSMN NewsFeed - 30 Sep 2019
Sobi to Acquire Dova Pharmaceuticals Creating a Global Growth Platform in Haematology
Sobi to Acquire Dova Pharmaceuticals Creating a Global Growth Platform in Haematology
HSMN NewsFeed - 26 Sep 2019
RaySearch Expands to a New Major Market With Distribution Agreement for Russia
RaySearch Expands to a New Major Market With Distribution Agreement for Russia
HSMN NewsFeed - 23 Sep 2019
Cologuard(R) Gains FDA Approval For Use In Younger Americans, Ages 45 To 49
Cologuard(R) Gains FDA Approval For Use In Younger Americans, Ages 45 To 49
HSMN NewsFeed - 29 Aug 2019
AbbVie Discontinues Rovalpituzumab Tesirine (Rova-T) Research and Development Program
AbbVie Discontinues Rovalpituzumab Tesirine (Rova-T) Research and Development Program
HSMN NewsFeed - 11 Jul 2019
RaySearch Receives FDA Clearance for RayStation 8B Including Machine Learning Functionalities
RaySearch Receives FDA Clearance for RayStation 8B Including Machine Learning Functionalities
HSMN NewsFeed - 28 Jun 2019
Amgen and UCB Provide Regulatory Update on Status of EVENITY(TM) (romosozumab) in the EU
Amgen and UCB Provide Regulatory Update on Status of EVENITY(TM) (romosozumab) in the EU
HSMN NewsFeed - 17 May 2019
Proton Therapy Center in Prague Becomes First Czech Clinic to Order RayStation
Proton Therapy Center in Prague Becomes First Czech Clinic to Order RayStation
HSMN NewsFeed - 29 Apr 2019
U.S. FDA Accepts New Drug Application and Grants Priority Review for Darolutamide
U.S. FDA Accepts New Drug Application and Grants Priority Review for Darolutamide
HSMN NewsFeed - 22 Apr 2019
Epic Sciences Appoints Richard J. Wenstrup, M.D. as Chief Medical Officer
Epic Sciences Appoints Richard J. Wenstrup, M.D. as Chief Medical Officer
HSMN NewsFeed - 5 Apr 2019
Hoag Radiation Oncology, USA, Selects RayStation as Their New Treatment Planning System
Hoag Radiation Oncology, USA, Selects RayStation as Their New Treatment Planning System
HSMN NewsFeed - 5 Mar 2019
The Oklahoma Proton Center, USA, Selects RayStation as its Treatment Planning System
The Oklahoma Proton Center, USA, Selects RayStation as its Treatment Planning System
HSMN NewsFeed - 24 Jan 2019
Merck KGaA, Darmstadt, Germany, Grants Exclusive License to Vertex for Two DNA Damage Response Inhibitors
Merck KGaA, Darmstadt, Germany, Grants Exclusive License to Vertex for Two DNA Damage Response Inhibitors
HSMN NewsFeed - 19 Oct 2018
Mylan and Biocon Announce Positive CHMP Opinion for Ogivri(R), Biosimilar Trastuzumab
Mylan and Biocon Announce Positive CHMP Opinion for Ogivri(R), Biosimilar Trastuzumab
HSMN NewsFeed - 24 Sep 2018
Cumberland Pharmaceuticals Announces Senior Music Industry Executive Joins Its Board Of Directors
Cumberland Pharmaceuticals Announces Senior Music Industry Executive Joins Its Board Of Directors
HSMN NewsFeed - 18 Sep 2018
Agendia and Genecast Biotechnology Partner to Launch MammaPrint(R) and BluePrint(R) in China
Agendia and Genecast Biotechnology Partner to Launch MammaPrint(R) and BluePrint(R) in China
HSMN NewsFeed - 30 Jul 2018
Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug Conjugate
Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug Conjugate
HSMN NewsFeed - 27 Jul 2018
Accord Healthcare’s (Intas) Pelgraz(R) (pegfilgrastim) Given Green Light by CHMP
Accord Healthcare’s (Intas) Pelgraz(R) (pegfilgrastim) Given Green Light by CHMP
HSMN NewsFeed - 26 Jul 2018
Phase 3 Study Of Subcutaneous Pertuzumab And Trastuzumab Initiated Using Halozyme's ENHANZE(R) Technology
Phase 3 Study Of Subcutaneous Pertuzumab And Trastuzumab Initiated Using Halozyme's ENHANZE(R) Technology
HSMN NewsFeed - 15 Jun 2018
MEI Pharma Presents Clinical Data on ME-401 at the European Hematology Association Congress
MEI Pharma Presents Clinical Data on ME-401 at the European Hematology Association Congress
HSMN NewsFeed - 8 Jun 2018
European Commission Approves Prolia(R) (denosumab) for Patients With Glucocorticoid-Induced Osteoporosis
European Commission Approves Prolia(R) (denosumab) for Patients With Glucocorticoid-Induced Osteoporosis
HSMN NewsFeed - 20 Mar 2018
Mylan Adds to Growing Oncology Portfolio with Launch of Generic Mutamycin(R) Injection
Mylan Adds to Growing Oncology Portfolio with Launch of Generic Mutamycin(R) Injection
HSMN NewsFeed - 27 Feb 2018
Amgen Receives Positive CHMP Opinion For Delivery System Of Neulasta(R) (pegfilgrastim)
Amgen Receives Positive CHMP Opinion For Delivery System Of Neulasta(R) (pegfilgrastim)
HSMN NewsFeed - 22 Feb 2018
GenomeDx Announces Inclusion of Decipher Genomic Testing in NCCN Guidelines for Prostate Cancer
GenomeDx Announces Inclusion of Decipher Genomic Testing in NCCN Guidelines for Prostate Cancer
HSMN NewsFeed - 19 Dec 2017
Agendia and Bluebee Partner to Bring New NGS-based MammaPrint(R) BluePrint(R) Breast Cancer Kit to Market
Agendia and Bluebee Partner to Bring New NGS-based MammaPrint(R) BluePrint(R) Breast Cancer Kit to Market
HSMN NewsFeed - 14 Dec 2017
Protagonist Therapeutics Appoints Sarah Noonberg, M.D., Ph.D. to the Board of Directors
Protagonist Therapeutics Appoints Sarah Noonberg, M.D., Ph.D. to the Board of Directors
HSMN NewsFeed - 1 Dec 2017
FDA approves first biosimilar for the treatment of certain breast and stomach cancers
FDA approves first biosimilar for the treatment of certain breast and stomach cancers
HSMN NewsFeed - 30 Nov 2017
Epic Sciences Launches Metastatic Breast Cancer Circulating Tumor Cell Panel
Epic Sciences Launches Metastatic Breast Cancer Circulating Tumor Cell Panel
HSMN NewsFeed - 25 Sep 2017
Cumberland Pharmaceuticals Launches Promotion of Totect(R) in The U.S. for Emergency Oncology Intervention
Cumberland Pharmaceuticals Launches Promotion of Totect(R) in The U.S. for Emergency Oncology Intervention
HSMN NewsFeed - 21 Sep 2017
European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma
European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma
HSMN NewsFeed - 11 Sep 2017
Oncolytics Biotech(R) Announces the Presentation of REOLYSIN(R) Clinical Data at ESMO 2017 Congress
Oncolytics Biotech(R) Announces the Presentation of REOLYSIN(R) Clinical Data at ESMO 2017 Congress
HSMN NewsFeed - 18 Aug 2017
EndoPredict(R) Receives Positive Coverage Decisions From Medicare and Anthem
EndoPredict(R) Receives Positive Coverage Decisions From Medicare and Anthem
HSMN NewsFeed - 21 Jul 2017
EMA's CHMP Issues Positive Opinion for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
EMA's CHMP Issues Positive Opinion for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
HSMN NewsFeed - 10 Jul 2017
FDA Grants Priority Review for Lilly's Abemaciclib for the Treatment of Advanced Breast Cancer
FDA Grants Priority Review for Lilly's Abemaciclib for the Treatment of Advanced Breast Cancer
HSMN NewsFeed - 4 Jul 2017
FDA Clears Expanded Use of Cooling Cap to Reduce Hair Loss During Chemotherapy
FDA Clears Expanded Use of Cooling Cap to Reduce Hair Loss During Chemotherapy
HSMN NewsFeed - 30 May 2017
Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration
Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration
HSMN NewsFeed - 9 May 2017
FDA Grants BAVENCIO(R) (avelumab) Approval for a Common Type of Advanced Bladder Cancer
FDA Grants BAVENCIO(R) (avelumab) Approval for a Common Type of Advanced Bladder Cancer
HSMN NewsFeed - 26 Apr 2017
FDA Approves XATMEP(TM), the First and Only Ready-To-Use Methotrexate Oral Solution
FDA Approves XATMEP(TM), the First and Only Ready-To-Use Methotrexate Oral Solution
HSMN NewsFeed - 19 Apr 2017
CytRx Announces FDA Agreement on Regulatory Pathway to Approval for Aldoxorubicin in Soft Tissue Sarcomas
CytRx Announces FDA Agreement on Regulatory Pathway to Approval for Aldoxorubicin in Soft Tissue Sarcomas
HSMN NewsFeed - 17 Apr 2017
OncoMed’s Phase 2 Trial of Tarextumab in Small Cell Lung Cancer Does Not Meet Endpoints
OncoMed’s Phase 2 Trial of Tarextumab in Small Cell Lung Cancer Does Not Meet Endpoints
HSMN NewsFeed - 3 Apr 2017
MEI Pharma Announces Appointment of Brian Drazba as Chief Financial Officer
MEI Pharma Announces Appointment of Brian Drazba as Chief Financial Officer
HSMN NewsFeed - 30 Mar 2017
Third Rock Ventures Launches Tango Therapeutics with $55 Million Series A Investment
Third Rock Ventures Launches Tango Therapeutics with $55 Million Series A Investment
HSMN NewsFeed - 27 Mar 2017
Dinutuximab beta receives positive recommendation for the treatment of high-risk neuroblastoma in Europe
Dinutuximab beta receives positive recommendation for the treatment of high-risk neuroblastoma in Europe
HSMN NewsFeed - 13 Mar 2017
Myriad Genetics Launches the EndoPredict(R) Test in the United States for Patients with Breast Cancer
Myriad Genetics Launches the EndoPredict(R) Test in the United States for Patients with Breast Cancer
HSMN NewsFeed - 8 Mar 2017
Celyad obtains FDA approval to initiate the NKR-2 CAR T cells THINK trial in the USA
Celyad obtains FDA approval to initiate the NKR-2 CAR T cells THINK trial in the USA
HSMN NewsFeed - 6 Mar 2017
Izun Pharmaceuticals Announces Approval of Curasite(TM) Hydrogel Wound Care Product by FDA
Izun Pharmaceuticals Announces Approval of Curasite(TM) Hydrogel Wound Care Product by FDA
HSMN NewsFeed - 17 Feb 2017
LYNPARZA(TM) (olaparib) Meets Primary Endpoint in Phase III Trial in BRCA-Mutated Metastatic Breast Cancer
LYNPARZA(TM) (olaparib) Meets Primary Endpoint in Phase III Trial in BRCA-Mutated Metastatic Breast Cancer
HSMN NewsFeed - 20 Jan 2017
Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer
Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer
HSMN NewsFeed - 6 Jan 2017
OncoGenex Pharmaceuticals, Inc. and Achieve Life Science, Inc. Announce Definitive Merger Agreement
OncoGenex Pharmaceuticals, Inc. and Achieve Life Science, Inc. Announce Definitive Merger Agreement
HSMN NewsFeed - 3 Jan 2017
Allergan Announces FDA Approval of NATRELLE INSPIRA(R) SoftTouch Breast Implants
Allergan Announces FDA Approval of NATRELLE INSPIRA(R) SoftTouch Breast Implants
HSMN NewsFeed - 19 Dec 2016
CytRx Appoints Chief Medical Officer Dr. Daniel Levitt as Chief Operating Officer
CytRx Appoints Chief Medical Officer Dr. Daniel Levitt as Chief Operating Officer
HSMN NewsFeed - 14 Nov 2016
Boston Biomedical Announces Orphan Drug Designation for Napabucasin in Pancreatic Cancer
Boston Biomedical Announces Orphan Drug Designation for Napabucasin in Pancreatic Cancer
HSMN NewsFeed - 18 Aug 2016
FDA Grants Soligenix Orphan Drug Designation for Dusquetide for Treatment of Macrophage Activation Syndrome
FDA Grants Soligenix Orphan Drug Designation for Dusquetide for Treatment of Macrophage Activation Syndrome
HSMN NewsFeed - 9 Aug 2016
AstraZeneca Provides Update On Phase III Trial Of Selumetinib In Non-Small Cell Lung Cancer
AstraZeneca Provides Update On Phase III Trial Of Selumetinib In Non-Small Cell Lung Cancer
HSMN NewsFeed - 26 Jul 2016
NCCN Guidelines Recommend Optune as a Standard Treatment Option for Newly Diagnosed Glioblastoma
NCCN Guidelines Recommend Optune as a Standard Treatment Option for Newly Diagnosed Glioblastoma
HSMN NewsFeed - 6 Jul 2016
FDA Grants Merrimack Fast Track Designation for Seribantumab (MM-121) in Non-small Cell Lung Cancer
FDA Grants Merrimack Fast Track Designation for Seribantumab (MM-121) in Non-small Cell Lung Cancer
HSMN NewsFeed - 17 Jun 2016
ARIAD Announces Distribution Agreements for Iclusig(R) in Latin America and the Middle East/North Africa
ARIAD Announces Distribution Agreements for Iclusig(R) in Latin America and the Middle East/North Africa
HSMN NewsFeed - 3 Jun 2016
Bayer and Orion Expand Clinical Development Program for BAY-1841788 (ODM-201) in Prostate Cancer
Bayer and Orion Expand Clinical Development Program for BAY-1841788 (ODM-201) in Prostate Cancer
HSMN NewsFeed - 24 May 2016
Amplyx Pharmaceuticals Appoints Paul C. Grint, M.D., to Board of Directors
Amplyx Pharmaceuticals Appoints Paul C. Grint, M.D., to Board of Directors
HSMN NewsFeed - 11 Apr 2016
FDA Grants Priority Review for Genentech’s Cancer Immunotherapy Atezolizumab in Specific Type of Lung Cancer
FDA Grants Priority Review for Genentech’s Cancer Immunotherapy Atezolizumab in Specific Type of Lung Cancer
HSMN NewsFeed - 6 Apr 2016
Merck and Sysmex Inostics Receive CE Mark Approval for Liquid Biopsy test for Colorectal Cancer Patients
Merck and Sysmex Inostics Receive CE Mark Approval for Liquid Biopsy test for Colorectal Cancer Patients
HSMN NewsFeed - 24 Mar 2016
Pivotal Phase III Trial of enzalutamide Initiated in Metastatic Hormone Sensitive Prostate Cancer
Pivotal Phase III Trial of enzalutamide Initiated in Metastatic Hormone Sensitive Prostate Cancer
HSMN NewsFeed - 12 Jan 2016
Inteplast Group’s Medegen Medical Products Awarded Novaplus(R) Contract for Specialty Bags
Inteplast Group’s Medegen Medical Products Awarded Novaplus(R) Contract for Specialty Bags
HSMN NewsFeed - 28 Dec 2015
Chimerix Announces Top-Line Results From Phase 3 SUPPRESS Trial of Brincidofovir
Chimerix Announces Top-Line Results From Phase 3 SUPPRESS Trial of Brincidofovir
HSMN NewsFeed - 21 Dec 2015
Roche receives FDA approval for HIV-1 viral load test on the cobas(R) 6800/8800 Systems
Roche receives FDA approval for HIV-1 viral load test on the cobas(R) 6800/8800 Systems
HSMN NewsFeed - 16 Dec 2015
BIND Therapeutics Appoints Jonathan Yingling, Ph.D., as Chief Scientific Officer
BIND Therapeutics Appoints Jonathan Yingling, Ph.D., as Chief Scientific Officer
HSMN NewsFeed - 10 Dec 2015
Lilly and Merck Expand Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA(R) Combination Trial
Lilly and Merck Expand Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA(R) Combination Trial
HSMN NewsFeed - 1 Dec 2015
Roche And Upsher-Smith Announce License Agreement To Develop Novel VAP-1 Inhibitor
Roche And Upsher-Smith Announce License Agreement To Develop Novel VAP-1 Inhibitor
HSMN NewsFeed - 30 Nov 2015
Proton Partners International to Fight Cancer with Elekta Radiotherapy Equipment
Proton Partners International to Fight Cancer with Elekta Radiotherapy Equipment
HSMN NewsFeed - 10 Nov 2015
Boston Scientific To Acquire Interventional Radiology Business Of CeloNova Biosciences
Boston Scientific To Acquire Interventional Radiology Business Of CeloNova Biosciences
HSMN NewsFeed - 5 Oct 2015
Novocure Announces CE Mark and First Patient Use of Second Generation Optune System
Novocure Announces CE Mark and First Patient Use of Second Generation Optune System
HSMN NewsFeed - 30 Sep 2015
J. Robert Paulson and Jeffrey Mathiesen Appointed to Sun BioPharma Board of Directors
J. Robert Paulson and Jeffrey Mathiesen Appointed to Sun BioPharma Board of Directors
HSMN NewsFeed - 5 Aug 2015
Mirati Therapeutics And MedImmune Partner On Immuno-Oncology Combination In Lung Cancer
Mirati Therapeutics And MedImmune Partner On Immuno-Oncology Combination In Lung Cancer
HSMN NewsFeed - 20 Jul 2015
BioMarin Provides Program Update for Talazoparib in Metastatic Breast Cancer
BioMarin Provides Program Update for Talazoparib in Metastatic Breast Cancer
HSMN NewsFeed - 2 Jun 2015
Advanced fPAT Imaging Announces Clinical First for the JBI-360(TM) Breast Imaging System
Advanced fPAT Imaging Announces Clinical First for the JBI-360(TM) Breast Imaging System
HSMN NewsFeed - 26 May 2015
Roche receives FDA clearance for the cobas(R) Cdiff Test to detect Clostridium difficile
Roche receives FDA clearance for the cobas(R) Cdiff Test to detect Clostridium difficile
HSMN NewsFeed - 6 May 2015
EMD Serono Initiates Co-Promotion of XALKORI(R) (crizotinib) with Pfizer in the United States
EMD Serono Initiates Co-Promotion of XALKORI(R) (crizotinib) with Pfizer in the United States
HSMN NewsFeed - 20 Apr 2015
Oasmia's Lead Cancer Product Paclical(R) Receives Market Approval in the Russian Federation
Oasmia's Lead Cancer Product Paclical(R) Receives Market Approval in the Russian Federation
HSMN NewsFeed - 18 Mar 2015
Hong Kong Authority Approves Abraxane(R) as First-Line Treatment For Late-Stage Pancreatic Cancer
Hong Kong Authority Approves Abraxane(R) as First-Line Treatment For Late-Stage Pancreatic Cancer
HSMN NewsFeed - 13 Mar 2015
Toshiba’s Aplio Platinum Series CV Helps Provide More Confident Cardiac Diagnoses
Toshiba’s Aplio Platinum Series CV Helps Provide More Confident Cardiac Diagnoses
HSMN NewsFeed - 3 Mar 2015
Oraya Therapeutics' AMD Radiotherapy Device Receives New Indication of Use for Choroidal Metastases
Oraya Therapeutics' AMD Radiotherapy Device Receives New Indication of Use for Choroidal Metastases
HSMN NewsFeed - 27 Feb 2015
FDA Approves Allergan’s NATRELLE INSPIRA(TM) Round Gel-Filled Breast Implants
FDA Approves Allergan’s NATRELLE INSPIRA(TM) Round Gel-Filled Breast Implants
HSMN NewsFeed - 18 Feb 2015
Biodesix Builds on Investments in Sales, Reimbursement and Government Affairs Growth Strategy
Biodesix Builds on Investments in Sales, Reimbursement and Government Affairs Growth Strategy
HSMN NewsFeed - 6 Jan 2015
CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results in Glioblastoma Multiforme (Brain Cancer)
CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results in Glioblastoma Multiforme (Brain Cancer)
HSMN NewsFeed - 29 Dec 2014
Roche receives FDA Emergency Use Authorization for the LightMix(R) Ebola Zaire rRT-PCR Test
Roche receives FDA Emergency Use Authorization for the LightMix(R) Ebola Zaire rRT-PCR Test
HSMN NewsFeed - 14 Aug 2014
FDA Approves Genentech’s Avastin Plus Chemotherapy for Treatment of Advanced Cervical Cancer
FDA Approves Genentech’s Avastin Plus Chemotherapy for Treatment of Advanced Cervical Cancer
HSMN NewsFeed - 22 Jul 2014
FDA Grants Genentech’s Avastin Priority Review for Recurrent Platinum-Resistant Ovarian Cancer
FDA Grants Genentech’s Avastin Priority Review for Recurrent Platinum-Resistant Ovarian Cancer
HSMN NewsFeed - 15 Jul 2014
FDA Grants Genentech’s Avastin Priority Review for Certain Types of Cervical Cancer
FDA Grants Genentech’s Avastin Priority Review for Certain Types of Cervical Cancer
HSMN NewsFeed - 11 Jun 2014
Lilly Announces Top-Line Results Of Phase III Hepatocellular Carcinoma Trial
Lilly Announces Top-Line Results Of Phase III Hepatocellular Carcinoma Trial
HSMN NewsFeed - 3 Jun 2014
Spinifex Pharmaceuticals Appoints Neuroscience Expert Dr Ronald Marcus as Chief Medical Officer
Spinifex Pharmaceuticals Appoints Neuroscience Expert Dr Ronald Marcus as Chief Medical Officer
HSMN NewsFeed - 27 May 2014
Spinifex Pharmaceuticals Strengthens Scientific Advisory Board (SAB) with Experts in Chronic Pain
Spinifex Pharmaceuticals Strengthens Scientific Advisory Board (SAB) with Experts in Chronic Pain
HSMN NewsFeed - 20 May 2014
Spero Therapeutics Appoints Thomas Parr, Ph.D. as Chief Scientific Officer
Spero Therapeutics Appoints Thomas Parr, Ph.D. as Chief Scientific Officer
HSMN NewsFeed - 5 May 2014
Immune Pharmaceuticals Announces Phase 3 Development and Commercialization Strategy for AMIKET
Immune Pharmaceuticals Announces Phase 3 Development and Commercialization Strategy for AMIKET
HSMN NewsFeed - 24 Apr 2014
FDA Approves Roche's HPV Test for First-Line Primary Screening for Cervical Cancer
FDA Approves Roche's HPV Test for First-Line Primary Screening for Cervical Cancer
HSMN NewsFeed - 21 Apr 2014
Spectrum Pharmaceuticals Promotes and Appoints Joseph Turgeon as President and Chief Operating Officer
Spectrum Pharmaceuticals Promotes and Appoints Joseph Turgeon as President and Chief Operating Officer
HSMN NewsFeed - 3 Mar 2014
Genentech Provides Update on Phase III Study of Onartuzumab in People with Specific Type of Lung Cancer
Genentech Provides Update on Phase III Study of Onartuzumab in People with Specific Type of Lung Cancer
HSMN NewsFeed - 19 Feb 2014
Lilly Announces Ramucirumab Phase III Lung Cancer Trial Meets Primary Endpoint of Overall Survival
Lilly Announces Ramucirumab Phase III Lung Cancer Trial Meets Primary Endpoint of Overall Survival
HSMN NewsFeed - 16 Jan 2014
CytRx Appoints Shanta Chawla, M.D. as Vice President, Clinical Development
CytRx Appoints Shanta Chawla, M.D. as Vice President, Clinical Development
HSMN NewsFeed - 15 Jan 2014
Competitive Tech's Calmare(R) Pain Device Therapy Garners Favorable Medicare Coverage Judgment
Competitive Tech's Calmare(R) Pain Device Therapy Garners Favorable Medicare Coverage Judgment
HSMN NewsFeed - 13 Jan 2014
Arno Therapeutics Expands Management Team With Additions of Two Scientific Leaders
Arno Therapeutics Expands Management Team With Additions of Two Scientific Leaders
HSMN NewsFeed - 13 Jan 2014
A.P. Pharma Announces Appointment of New Directors and Effective Date of Name Change and Reverse Stock Split
A.P. Pharma Announces Appointment of New Directors and Effective Date of Name Change and Reverse Stock Split
HSMN NewsFeed - 6 Jan 2014
PIXUVRI(R) (pixantrone) Receives Positive Final Appraisal Determination from NICE
PIXUVRI(R) (pixantrone) Receives Positive Final Appraisal Determination from NICE
HSMN NewsFeed - 20 Dec 2013
Cellceutix Files Orphan Drug Designation Application for Brilacidin for Oral Mucositis with US FDA
Cellceutix Files Orphan Drug Designation Application for Brilacidin for Oral Mucositis with US FDA
HSMN NewsFeed - 16 Dec 2013
Premier Biomedical Secures $5 Million Equity Funding From Kodiak Capital Group, LLC
Premier Biomedical Secures $5 Million Equity Funding From Kodiak Capital Group, LLC
HSMN NewsFeed - 4 Dec 2013
Cell Therapeutics and GKV-SV Reach Agreement on Pricing of PIXUVRI(R) (pixantrone) in Germany
Cell Therapeutics and GKV-SV Reach Agreement on Pricing of PIXUVRI(R) (pixantrone) in Germany
Additional items found! 500
Members Archive contains
500 additional stories matching:
chemotherapy
(Password required)
chemotherapy
(Password required)